Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Eight cell stage

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    22 result(s) found for: Eight cell stage. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2020-002453-26 Sponsor Protocol Number: 73908 Start Date*: 2020-11-18
    Sponsor Name:Rigshospitalet
    Full Title: Eight weeks of androgen priming by hCG before IVF/ICSI in women with low ovarian reserve.
    Medical condition: Female Infertility
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004872 10016399 Female infertility (primary) LLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-005729-25 Sponsor Protocol Number: LUNGVAC Start Date*: 2022-05-09
    Sponsor Name:Vestre Viken Health Trust
    Full Title: A Randomized Phase II, Open-label, Multicenter Study Investigating Efficacy and Safety of anti-PD-1/PD-L1 treatment +/- UV1 vaccination as first line treatment in patients with inoperable advanced ...
    Medical condition: Inoperable advanced or metastatic non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029520 Non-small cell lung cancer stage IIIA PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050017 Lung cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025044 Lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-013838-25 Sponsor Protocol Number: IMCLCP11-0806 Start Date*: 2009-10-21
    Sponsor Name:ImClone LLC
    Full Title: A Randomized, Multicenter, Open-Label, Phase 3 Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Gemcitabine-Cisplatin Chemotherapy Alone in the First-Line Treatment of...
    Medical condition: Advanced squamous non small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) AT (Completed) DE (Completed) HU (Completed) PT (Completed) ES (Ongoing) GR (Ongoing) SK (Completed) IT (Completed) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-000142-37 Sponsor Protocol Number: XM01-06 Start Date*: 2005-06-13
    Sponsor Name:BioGeneriX AG
    Full Title: Efficacy and Safety of subcutaneous administration of XM01 compared to Epoetin beta in anaemic chronic renal failure patients not yet receiving dialysis and in maintenance phase treatment with Epoe...
    Medical condition: anaemic chronic renal failure patients not yet receiving dialysis
    Disease: Version SOC Term Classification Code Term Level
    9 10009119 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2006-005032-25 Sponsor Protocol Number: Vx-001/202 Start Date*: 2007-05-08
    Sponsor Name:Vaxon Biotech
    Full Title: A multi-centre phase II controlled study of Vx-001 in Non Small Cell Lung Cancer (NSCLC)
    Medical condition: Patients with Non Small Cell Lung Cancer (NSCLC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-012574-12 Sponsor Protocol Number: IMCLCP11-0805 Start Date*: 2009-09-14
    Sponsor Name:ImClone LLC
    Full Title: A Randomized, Multicenter, Open-Label Phase 3 Study of Pemetrexed-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Pemetrexed-Cisplatin Chemotherapy Alone in the First-Line Treatment of Pa...
    Medical condition: Advanced nonsquamous non small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) BE (Completed) HU (Completed) PT (Completed) DE (Completed) ES (Completed) GR (Completed) SK (Completed) IT (Completed) FR (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2005-004630-41 Sponsor Protocol Number: H6Q-MC-JCBJ Start Date*: 2006-04-26
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin
    Medical condition: high-risk diffuse large B-cell lymphoma (DLBCL )
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004851 10012819 Diffuse large B-cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) HU (Completed) ES (Prematurely Ended) DK (Prematurely Ended) BE (Prematurely Ended) PT (Prematurely Ended) DE (Prematurely Ended) GR (Prematurely Ended) IT (Completed) GB (Prematurely Ended) CZ (Prematurely Ended) FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004510-28 Sponsor Protocol Number: IM-201 Start Date*: 2015-03-05
    Sponsor Name:Immunicum AB
    Full Title: An open-label, randomized, controlled, multicenter, phase II study evaluating safety and efficacy of intratumorally administered Intuvax pre-nephrectomy followed by Sunitinib post-nephrectomy, comp...
    Medical condition: Metastatic Renal Cell Carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) HU (Completed) LV (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-012709-20 Sponsor Protocol Number: LF-0207 Start Date*: 2009-10-21
    Sponsor Name:Agennix Incorporated
    Full Title: A Phase 3, randomized, double-blind, placebo-controlled study of oral talactoferrin in addition to best supportive care in patients with non-small cell lung cancer who have failed two or more prior...
    Medical condition: Non-small cell lung cancer in patients who have failed two or more prior treatment regimens.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) LV (Completed) FR (Ongoing) HU (Completed) DE (Completed) ES (Ongoing) GR (Completed) BG (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-004928-21 Sponsor Protocol Number: Auto-Allo-TSCTinMM Start Date*: 2008-06-27
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: Autologous-Allogeneic Tandem Stem Cell Transplantation and Maintenance Therapy with Thalidomide / DLI for patients with Multiple Myeloma (MM) and age <= 60 years: A phase II-study
    Medical condition: Multiple Myeloma Stage II or III according to Salmon and Durie
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005391-13 Sponsor Protocol Number: OCTO_005 Start Date*: 2008-10-20
    Sponsor Name:University of Oxford [...]
    1. University of Oxford
    2. Royal Wolverhampton Hospitals NHS Trust
    Full Title: Cancer Oesophagus Gefitinib(COG) - Phase III randomised, double-blind, placebo-controlled trial of gefitinib (Iressa®) versus placebo in oesophageal cancer progressing after chemotherapy.
    Medical condition: Oesophageal cancer (adenocarcinoma and squamous cancers).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001141 Adenocarcinoma LLT
    9.1 10041824 Squamous cell carcinoma of esophagus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-002617-35 Sponsor Protocol Number: BUL-5/ESD Start Date*: 2019-08-20
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, randomised, placebo-controlled, phase IIa trial on the efficacy and tolerability of an 8-week treatment with two different doses of budesonide orodispersible tablets vs. placebo for p...
    Medical condition: Prevention of oesophageal strictures in adult patients after endoscopic submucosal dissection
    Disease: Version SOC Term Classification Code Term Level
    25.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030186 Oesophageal squamous cell carcinoma NOS LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030137 Oesophageal adenocarcinoma PT
    20.0 10017947 - Gastrointestinal disorders 10004137 Barrett's oesophagus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Restarted) PT (Trial now transitioned) NL (Trial now transitioned) BE (Completed) SE (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-023083-40 Sponsor Protocol Number: SPON830-10 Start Date*: 2012-03-19
    Sponsor Name:Cardiff University
    Full Title: A Phase II study of neoadjuvant chemotherapy given before SCPRT as treatment for patients with MRI-staged operable rectal cancer at high risk of metastatic relapse
    Medical condition: Rectal adenocarcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-004577-12 Sponsor Protocol Number: BRF116613 Start Date*: 2015-03-23
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: Phase II biomarker study evaluating the upfront combination of BRAF inhibitor dabrafenib with MEK inhibitor trametinib versus the combination after eight weeks of monotherapy with dabrafenib or tra...
    Medical condition: patients with metastatic and unresectable stage III or IV melanoma harbouring an activating BRAF mutation
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10027156 Skin melanomas (excl ocular) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-005286-41 Sponsor Protocol Number: CF102-301HCC Start Date*: 2022-12-08
    Sponsor Name:CanFite BioPharma Ltd.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients with Child-Pugh Class B7 Ci...
    Medical condition: Advanced Hepatocellular Carcinoma in Patients with Child-Pugh Class B7 Cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Trial now transitioned) PL (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-001267-63 Sponsor Protocol Number: SIOPENRNET001 Start Date*: 2005-07-15
    Sponsor Name:St. Anna Kinderspital
    Full Title: Bridging study using ch14.18/CHO antibody in children with refractory neuroblastoma
    Medical condition: neuroblastoma
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-004311-23 Sponsor Protocol Number: HOTstudy_Thomas11 Start Date*: 2011-11-29
    Sponsor Name:University of Edinburgh [...]
    1. University of Edinburgh
    2. NHS Lothian
    Full Title: A randomised, placebo controlled trial to study the effect of heme-arginate on heme-oxygenase-1 induction and renal function in recipients of deceased donor renal transplants.
    Medical condition: Ischaemia-reperfusion injury in renal transplantation
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004857 10014646 End stage renal disease (ESRD) LLT
    20.0 100000004865 10023438 Kidney transplant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2015-003892-31 Sponsor Protocol Number: MedOPP089 Start Date*: 2017-03-23
    Sponsor Name:Medica Scientia Innovation Research (MedSIR)
    Full Title: A multicenter, international, non-controlled, phase II trial to identify the molecular mechanisms of resistance and sensitivity to palbociclib re-challenge upon progression to a palbociclib combina...
    Medical condition: Patients with hormone receptor (HR)-positive/HER2-negative locally advanced or metastatic breast cancer (mBC). Second/third-line of endocrine treatment.
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001489-17 Sponsor Protocol Number: SIOPENRNET003 Start Date*: 2006-11-17
    Sponsor Name:St. Anna Kinderkrebsforschung e.V.
    Full Title: High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN)
    Medical condition: High Risk Neuroblastoma
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Completed) ES (Restarted) GB (GB - no longer in EU/EEA) BE (Completed) DK (Restarted) IT (Completed) IE (Completed) HU (Completed) FI (Completed) SI (Completed) PL (Completed) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000251-14 Sponsor Protocol Number: FIL_FLAZ-12 Start Date*: 2013-10-08
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: A PHASE III MULTICENTER, RANDOMIZED STUDY COMPARING CONSOLIDATION WITH (90)YTTRIUM-LABELED IBRITUMOMAB TIUXETAN (ZEVALIN®) RADIOIMMUNOTHERAPY VS AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN PATIE...
    Medical condition: Patients aged 18-65 years with follicular lymphoma in first or second relapse
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016905 Follicle centre lymphoma, follicular grade I, II, III recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 15:13:45 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA